Evolus (NASDAQ:EOLS) Price Target Raised to $25.00 at Barclays

Evolus (NASDAQ:EOLS) had its price objective increased by Barclays from $22.00 to $25.00 in a research report sent to investors on Wednesday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other equities research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Friday, February 14th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Tuesday, January 21st.

Evolus Trading Down 1.3 %

Shares of NASDAQ:EOLS opened at $14.17 on Wednesday. Evolus has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a market capitalization of $897.26 million, a P/E ratio of -15.57 and a beta of 1.33. The company has a 50-day simple moving average of $12.79 and a 200 day simple moving average of $14.08. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Institutional Investors Weigh In On Evolus

Hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new stake in Evolus during the fourth quarter worth approximately $49,000. IFP Advisors Inc lifted its position in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after acquiring an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $118,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.